GASTROESOPHAGEAL JUNCTION CANCER
Clinical trials for GASTROESOPHAGEAL JUNCTION CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION CANCER trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug tested in patients with advanced stomach and gut cancers
Disease control TerminatedThis early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to target a protein called CLDN18.2 found on some cancer cells. The main goals …
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Phase: PHASE1 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Early trial of experimental cancer combo halted after 21 patients
Disease control TerminatedThis early-stage study tested an experimental oral drug (PF-07265028) alone or combined with an immunotherapy injection (sasanlimab) in 21 people with advanced solid tumors, including stomach, lung, and head/neck cancers. The main goals were to find a safe dose and check for side…
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill targets Hard-to-Treat cancers in early human test
Disease control TerminatedThis early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug combo tested for Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors such as head and neck or gastrointestinal cancers. The study aimed to find safe doses and check for early signs of effectiveness. It …
Matched conditions: GASTROESOPHAGEAL JUNCTION CANCER
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 26, 2026 12:43 UTC